A Phase III, Multicenter, Uncontrolled, Open Label Study to Evaluate Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011, When Administered to Adult and Elderly Subjects.
Latest Information Update: 11 Mar 2021
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Novartis
- 13 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2010 New trial record